Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "FDC"

23 News Found

Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.

Glenmark launches novel fixed-dose combination for diabetes
Drug Approval | October 26, 2021

Glenmark launches novel fixed-dose combination for diabetes

It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets
News | July 01, 2021

Lupin receives tentative U.S. FDA approval for Dolutegravir, Lamivudine and TLD tablets

TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg

Latest Stories

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging